MedTrace Logo

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-02-01

No results posted yet for this study

Summary

Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality. It may also serve as biomarker for very early risk stratification. The aim of this study is to compare the outcomes for patients with elevated IL-10 levels (≥8 pg/ml) when treated with standard antibiotic therapy (daptomycin or vancomycin) versus early aggressive therapy (daptomycin with ceftaroline) for the treatment of MRSaB.

Conditions

  • Bacteremia

Interventions

DRUG

Daptomycin

Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.

DRUG

Vancomycin

Control Arm Treatment

DRUG

Ceftaroline

Study Arm Treatment

Sponsors & Collaborators

  • Sharp HealthCare

    lead OTHER

Principal Investigators

  • DeAnn Cary, PhD · Sharp HealthCare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-09-15
Completion
2018-01-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660346 on ClinicalTrials.gov